SRF Q3 FY26 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹3,713 Cr
verified against source
Revenue YoY
6%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
SRF delivered Q3 FY26 results with 6% YoY revenue growth to ₹3,713 crore and strong PAT expansion of 60% to ₹433 crore, driven by record performance in fluorochemicals (refrigerant segment). Chemicals business grew 22% to ₹1,825 crore on higher refrigerant volumes and operational efficiencies. However, specialty chemicals face persistent Chinese pricing pressure causing margin contraction of 170-180bps sequentially, with management choosing market share protection over profitability. Performance films (₹1,342 crore, -3% YoY) and technical textiles (₹454 crore) remain under pressure from cheaper Chinese imports and weak domestic demand. The Kigali Amendment quota regime constrains HFC capacity expansion, creating a structural advantage for existing players like SRF. Management guides for Q4 specialty chemicals improvement driven by pent-up demand deferrals. US tariff uncertainty on R32 has shifted customers to month-to-month purchasing, while the new-generation gases project at Odisha (₹1,500-2,000 crore Phase 1 capex) remains on track. Pharma intermediates business (currently ~10% of chemicals) is expanding with a second ₹180 crore plant, targeting 20% portfolio share. The key risk is specialty chemicals pricing environment potentially remaining subdued if Chinese competitors maintain irrational price levels, which remains difficult to predict.
Colored figures show movement against the previous available record.
Guidance to track
- On track for previously guided capex; Phase 1 investment at new Odisha site for next-generation gases expected in ₹1,500-2,000 crore range, with ancillary plants requiring board approval.
- Investment of ₹180 crore at existing Dahej site for second pharma intermediates plant, expected commissioning in approximately 8 months to capture growing pharma pipeline.
- Management expects Q4 to be substantially better driven by pent-up demand deferrals from Q2 and Q3, with POs already in hand. However, full revival remains contingent on Chinese pricing correction timing.
- Active ingredient pipeline for agrochemicals remains on schedule with one AI launch expected in FY26 and two additional AIs in FY27; registrations progressing as planned.
Risks flagged
- Chinese players maintaining irrational pricing across core specialty chemical products, forcing SRF to protect market share over margins. Sequential margin contraction of 170-180bps observed. Timing of Chinese correction remains unpredictable.
- R32 falls under US tariffs unlike R134a, causing customers to shift from annual contracts to month-to-month purchasing. Increased transaction costs and business reallocation from India to Thailand plant to avoid tariffs, raising logistics costs.
- BOP/BOPET volumes impacted by GST 2.0 repackaging requirements and cheap Chinese imports. Technical textiles facing sustained pressure on belting fabrics due to aggressive Chinese pricing and reduced conveyor belt exports to US. Margins unlikely to improve near-term.
- Demand deferment for key agro products continues despite management expressing confidence in revival signs. Analyst pressed on lead indicators for cycle turn; management cited global commodity prices normalization (soya) as key signal. One AI launch tracking for FY26 per earlier guidance.
Key quotes
- We have consciously chosen to protect our market share and volumes. From our discussions with stakeholders, it is evident that Chinese players are finding it difficult to sustain these price levels and we believe that this situation is not viable in the long run. When this correction will happen remains difficult to predict at this stage.
- Our fluochemicals business has delivered a record quarter in all counts. The refrigerants segment performed exceptionally well despite this being traditionally lean season, supported by firm global HFC prices driven by China's Kigali-aligned supply restrictions and steady international demand.
- The question is not if but when that will happen. So I think this seems to be the sort of the Chinese way where you come in and bombard the market with volume and low pricing but at some stage people also need returns and I think that's something that will change the environment in China going forward.
Research modules